+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Menses and breast cancer: does timing of mammographically directed core biopsy affect outcome?



Menses and breast cancer: does timing of mammographically directed core biopsy affect outcome?



Journal of Surgical Oncology 74(3): 232-236



Studies have shown molecular, genetic and cellular changes in breast cancer during the menstrual cycle. Changes in proliferative and metastatic potential of breast cancer cells during menses could explain improved survival when tumors are surgically removed in the luteal phase. This study examined if timing of mammography/core biopsy (MAM-CB) also affected breast cancer prognosis (histological tumor grade). Eighty-five premenopausal women undergoing MAM-CB at one clinic between March 1995 and February 1998 were retrospectively studied. All patients had Stage I or II breast cancer surgically treated. Patients were grouped by phase of menses at MAM-CB: follicular (F, Days 0-14) or luteal (L, Days 15-35). Groups were comparable in age, menarche, family history, nulliparity, breastfeeding, and total percentage of clinically palpable tumors. Pathological characteristics of the tumors (tumor size, tumor type, estrogen and progesterone receptor status, axillary lymph node status, the presence of lymphatic or vascular invasion and extranodal metastasis) was also comparable across the 2 groups. Low-grade tumors were more frequent in the MAM-CB group L, whereas high-grade tumors were more common in the MAM-CB group F (P = 0.002, chi2(4) = 17.06). Timing of MAM-CB in relation to menses may be a factor influencing breast cancer outcome. Future studies examining the effect of menses on the outcome of breast cancer should consider the potential effect of the timing of MAM-CB.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 046664058

Download citation: RISBibTeXText

PMID: 10951425

DOI: 10.1002/1096-9098(200007)74:3<232::aid-jso16>3.0.co;2-i


Related references

Mammographically detected breast cancer. Benefits of stereotactic core versus wire localization biopsy. Annals of Surgery 223(6): 688-97; Discussion 697-700, 1996

Mammographically directed breast biopsy. Southern Medical Journal 84(9): 2S83, 1991

Mammographically directed biopsy of nonpalpable breast lesions. Archives of Surgery 102(4): 292-295, 1971

Predictors of invasive breast cancer in mammographically detected microcalcification in patients with a core biopsy diagnosis of flat epithelial atypia, atypical ductal hyperplasia or ductal carcinoma in situ and recommendations for a selective approach to sentinel lymph node biopsy. Pathology, Research and Practice 208(4): 217-220, 2012

Breast cancer prognosis and isolated tumor cell findings in axillary lymph nodes after core needle biopsy and fine needle aspiration cytology: Biopsy method and breast cancer outcome. European Journal of Surgical Oncology 42(1): 64-70, 2016

Protocol for the pathologic examination and tissue processing of the mammographically directed breast biopsy. Pathology 1(1): 23-45, 1992

Processing the small invasive carcinoma detected in the mammographically directed breast biopsy. Pathology 1(1): 51-64, 1992

Significance of DNA content and proliferative rate of the invasive carcinoma found in the mammographically directed breast biopsy. Pathology 1(1): 137-160, 1992

Diagnostic accuracy of perforated compression grid approach for mammographically guided core needle biopsy of breast lesions. Cancer Letters 146(2): 181-188, 2000

Diagnostic accuracy of perforated compression grid approach for mammographically guided core needle biopsy of breast lesions. Cancer Letters 146(2): 181-188, Nov 15, 1999

Stereotactic core biopsy reduces the reexcision rate and the cost of mammographically detected cancer. Journal of Surgical Research 78(1): 23-26, 1998

Does the timing of breast cancer surgery in pre-menopausal women affect clinical outcome? An update. International Seminars in Surgical Oncology 3: 37-37, 2006

Management of Clinically and Mammographically Occult Benign Papillary Lesions Diagnosed at Ultrasound-Guided 14-Gauge Breast Core Needle Biopsy. Journal of Ultrasound in Medicine 35(11): 2325-2332, 2016

Does timing of breast cancer surgery in relation to the menstrual cycle phase affect prognosis? The Yorkshire Breast Cancer Group Intervention, Timing and Survival Study. Journal of Clinical Oncology 23(16_suppl): 536-536, 2016

Long-term outcome in mammographically detected invasive breast cancer treated with breast conserving therapy. International Journal of Radiation Oncology Biology Physics 36(1 SUPPL ): 279, 1996